Fig 1: Cutaneous expression of IL-31 by immunohistochemistry staining from a prurigo nodularis (PN) patient and a healthy subject (HS): (a) (original magnification ×400). Comparison of IL-31 expression in the epidermis (b) and dermis (c) between PN patients and healthy subjects, evaluated by immunohistochemistry. Epidermal and dermal expression of IL-31 were significantly higher in PN patients than in healthy subjects.
Fig 2: Periostin in prurigo nodularis (PN). Representative images of PN lesions and healthy individual (HI) skin with quantification of staining. (A) Dermal expression of periostin was significantly enhanced in PN lesions and correlated with itch intensity. White dotted circles indicate the epidermis excluding the stratum corneum. Black lines in the center panel represent medians. (B) Dermal periostin did not correlate with the number of dermal IL- 31(+) cells, IL-31RA(+) cells, and OSMRß(+) cells. Bar = 1 mm. AU: arbitrary unit; r: Spearman’s rank correlation coefficient; NRS: numerical rating scale.
Fig 3: Paeonol inhibits the mRNA and protein expression levels of cytokines that mediate inflammatory and immune reactions. mRNA expression levels of (A) IL-4, (B) IL-13, (C) IL-31 and (D) TSLP. Protein expression levels of (E) IL-4, IL-13, IL-31 and TSLP in the lesions. (F) Protein expression levels were semi-quantified. Data are presented as the means ± standard deviation (n=6). *P<0.05, **P<0.01 vs. the control group; #P<0.05 vs. the model group. IL, interleukin; Pae-H, paeonol-high (200 mg/kg); Pred, prednisolone; TSLP, thymic stromal lymphopoietin.
Fig 4: Comparison of serum IL-31 levels between PN patients and healthy subjects. Serum IL-31 levels were significantly higher in PN patients than in healthy subjects.
Supplier Page from Abcam for Anti-IL-31 antibody